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Glycogen synthase kinase-3β (GSK-3β)i sk n o w nt oa ﬀect a diverse range of biological functions controlling gene expression,
cellular architecture, andapoptosis.GSK-3β hasrecently been identiﬁed asoneof the important pathogenic mechanismsin motor
neuronaldeath related to amyotrophiclateral sclerosis (ALS).Therefore, the development of methods to control GSK-3β could be
helpful in postponing the symptom progression of ALS. Here we discuss the known roles of GSK-3β in motor neuronal cell death
in ALS and the possibility of employing GSK-3β modulators as a new therapeutic strategy.
1.Introduction
Amyotrophic lateral sclerosis (ALS), characterized by pro-
gressive muscle wasting and weakness, is a progressive, fatal
neurodegenerative disorder characterized by the preferen-
tial loss of motoneurons. The precise pathogenic mech-
anisms on motoneuron death need to be clearly eluci-
dated, although several theories, including oxidative stress,
glutamate toxicity, calcium-mediated toxicity, neurotrophic
factor withdrawal, genetic defects, immune-inﬂammation,
and accumulationof abnormal proteins, have beenproposed
as pathogenic mechanisms of familial/sporadic ALS [1–
8]. However, recent discoveries of copper-zinc superoxide
dismutase (SOD1) mutant genes, which cause familial ALS,
have signiﬁcantly contributed to the current understanding
of the pathogenic mechanisms of ALS [1, 4–8].
Glycogen synthase kinase-3 (GSK-3), originally identi-
ﬁ e da sar e g u l a t o ro fg l y c o g e ns y n t h e s i s[ 9], is now known to
be a multifaceted enzyme aﬀecting a diverse range of biolog-
ical functions from gene expression to cellular architecture
and apoptosis [10]. Two closely related isoforms of GSK-3,
GSK-3α,a n dG S K - 3 β, exist in mammals [11]. GSK-3β has
more important roles than GSK-3α in the nervous system.
Moreover, the role of GSK-3β has been identiﬁed as one of
the important enzymes regulating pathogenic mechanisms
of Alzheimer’s disease (AD) and Parkinson’s disease (PD).
The abnormal increase in the level and activity of GSK-
3β has been associated with neuronal death, paired helical
ﬁlament tau formation, and neurite retraction in AD and
in GSK-3β mediated 6-hydroxydopamine-induced neuronal
death in in vitro and in vivo models of PD [12–14]. Recently,
it has been reported that the role of GSK-3β is important in
the pathogenic mechanisms of ALS. For example, GSK-3β is
increased in the thoracic spinal cord tissue of patients with
sporadic ALS and in motoneurons transfected with G93A or
the A4V mutant hSOD1 gene [13, 15].
In this review, we will focus our discussion on the
following topics: (1) a description of GSK-3β, (2) the role
of GSK-3β in neuronal cell death, (3) the role of GSK-3β in
ALS, and (4) the development of new GSK-3β inhibitors.
2.A Descriptionof GSK-3β
GSK-3 is a serine/threonine protein kinase and a key enzyme
involved in glycogen metabolism [16]. Activated GSK-3
phosphorylatesandinactivatesglycogensynthase,converting
glucose to glycogen. In mammals, GSK-3 is encoded by
distinct two genes, GSK-3α and GSK-3β [11]. GSK-3α and
GSK-3β are constitutively active and usually phosphorylate
substrates that are prephosphorylated. Especially focused2 Neurology Research International
on GSK-3β, many studies have shown that GSK-3β is
activated by phosphorylation of the tyrosine 216 residue
(Tyr216) located in the kinase domain and inactivated by
phosphorylation of the amino-terminal serine 9 residue
(Ser9) and that GSK-3β participates in a variety of cellular
processes, including the insulin and Wnt/wingless signaling
pathways, and in the regulation of metabolic, structural,
and signaling protein functions, such as activator protein-1,
cyclic AMP response element binding protein, the nuclear
factor of activated T cells, heat shock factor-1, and β-
catenin [10, 16–20]. GSK-3β is also known to directly aﬀect
the CCAAT/enhancer binding protein, Myc; the heat shock
transcription factor-1 (HSTF-1), tau; nuclear factor κB
(NFκB); p53; caspase-3; the release of cytochrome c [15–20].
The activity of GSK-3β is negatively regulated by insulin.
Speciﬁcally,insulin enhancestheactivation ofphosphatidyli-
nositol 3-kinase (PI3K), which in turn increases the expres-
sion of antiapoptotic proteins and inhibits the activity
of proapoptotic proteins. PI3K activates the downstream
target Akt/protein kinase B by phosphorylating it. Phos-
phorylated Akt (pAkt) subsequently phosphorylates and
inhibits GSK-3β. When excessive stress occurs, however,
cell death is induced and activates the phosphatase and
tensin homolog (PTEN), a 3-phosphatase that converts
PI(3,4)P2 toPI(4)Pand PI(3,4,5)P3 toPI(4,5)P2,i nc e l l s ,a n d
activated PTEN then inactivates PI3K via the suppression of
PI(3,4,5)P3.Inactivated PI3Kcannot phosphorylate Akt,and
the decrease in pAkt reduces phosphorylation of GSK-3β,a l l
of which causes an increase in the active form of GSK-3β
[15–20]. Activated GSK-3β inhibits HSTF-1, resulting in the
mitochondrial death pathway and the release of cytochrome
c from mitochondria. Finally, released cytochrome c induces
apoptosis by activating caspase-9 and caspase-3 [21–23].
GSK-3β is also involved in the Wnt signaling pathway, which
also inhibits GSK-3β activity and the phosphorylation and
degradation of substrates by GSK-3β [24, 25].
Regarding GSK-3βlocalization, GSK-3βhas traditionally
been classiﬁed as a predominantly cytosolic enzyme [26];
however, it was recently shown that smaller but much more
active pools of GSK-3β a r ep r e s e n ti nt h en u c l e u sa n d
mitochondria [18].
3.TheRoleofGSK-3β inNeuronal CellDeath
As described above, there are two isoforms of GSK-3 in
mammals, GSK-3αand GSK-3β.G S K - 3 β is more prominent
in the nervous system and has been reported to play an
important role in neuronal cell death [15, 19, 27], although
it has recently been proposed that GSK-3α also plays a role
in this process [28]. GSK-3β has been identiﬁed as one of the
principalenzymes involvedin the pathogenicmechanisms of
neurodegenerative disorders and ischemic stroke.
There are numerous studies showing that abnormal
increases in the level and activity of GSK-3β induce neuronal
cell death paired helical ﬁlament tau formation, and neurite
retraction in Alzheimer’s disease (AD) [14]. In particular, it
is commonly accepted that amyloid beta protein activates
GSK-3β,a n da c t i v a t e dG S K - 3 β mediates phosphorylation
of tau protein, induces neuronal cell death, and disrupts
axonal transport through an NMDA receptor-dependent
mechanism [29].
GSK-3β is also known to participate in the pathogenesis
of PD [12]. α-Synuclein protein deposition into Lewy bodies
is a pathologic marker of PD, and α-Synuclein induces neu-
rotoxicity.In addition, GSK-3β is thought tobe important in
α-Synuclein-induced neurotoxicity. It has been reported that
α-Synuclein activates GSK-3β, enabling the hyperphospho-
rylation of tau proteins; however, the precise mechanism by
which α-Synuclein contributes to the activation of GSK-3β
remains to be elucidated [30].
In stroke, GSK-3β has been reported to be involved
in neuronal cell death, whereas treatment with GSK-3β
inhibitors in the acute state reduces infarction volume and
improves neurobehavioral function [31, 32]. In the chronic
state, GSK-3β inhibitors promote neurovascular remodeling
after stroke and improve postischemic stroke sequelae [33,
34].
4.TheRoleofGSK-3β inALS?
Recent studies have reported that an abnormal increase in
GSK-3β is found in in vitro and in vivo models of ALS, in
the thoracic spinal cord tissue of patients with sporadic ALS
[13],andinthefrontalandtemporalcorticesofALSpatients.
Moreover, its suppression attenuates disease progression in
an ALSmouse model [35–37]. Speciﬁcally, Huet al. reported
that protein kinases, such as GSK-3β,a r ei n c r e a s e di nt h e
thoracic spinal cord tissue of patients with sporadic ALS
[13]. Yang et al. reported that the expression of GSK-3β
and phospho-beta-catenin, which reﬂects the activity of
GSK-3β, was increased in ALS patients compared to that
of controls and that GSK-3β immunoreactive neurons were
mainly located in layer II and layer III of the frontal cortex
and in layer II of the hippocampus [35]. In our previous
ﬁndings, bothGSK-3βexpressionandactivitywereincreased
in motorneurons transfected with the G93A,or A4Vmutant
hSOD1 genes and in motor neurons transfected with the
G93A or A4V mutant hSOD1 genes [15, 38]. Taken together,
these ﬁndings support the potential role for GSK-3β as a
therapeutic target in ALS.
There have been many studies showing that GSK-3β
inhibition can suppress disease progression of ALS in both
in vitro and in vivo m o d e l s .W eh a v er e p o r t e dt h a tG S K - 3 β
inhibition, using a speciﬁc inhibitor or using materials with
GSK-3βinhibitoryeﬀects,reducedmotorneuronalcelldeath
in motor neurons transfected with the G93A or A4V mutant
hSOD1 genes in an in vitro model of ALS [15, 39]. Recently,
Calder´ o et al. also reported that lithium, a GSK-3β inhibitor,
prevents the excitotoxic cell death of motor neurons [40].
Feng et al. and our group also reported that disease onset,
disease progression, and survival in ALS mouse models were
prolonged by the treatments of speciﬁc inhibitors of GSK-
3β ormaterials with GSK-3β inhibitor eﬀects. The protective
mechanisms of GSK-3β inhibition in in vitro and in vivo
models of ALS are as follows. GSK-3β inhibition decreases
motoneuronalcelldeathbyrestoringsurvival-related signals,Neurology Research International 3
Table 1: New GSK-3β inhibitors under development.
Inhibitor Class IC50 (mM)
GSK-3α GSK-3β
ARA014418 Thiazole — 0.1040
CHIR98014 Aminopyrimidine 0.0007 0.0006
CHIR99021 (CT99021) Aminopyrimidine 0.0100 0.0070
Compound 17 Chloromethyl thienyl ketone — 1.0000
Compound 1A Pyrazolopyrimidine — 0.0160
Compound 29 Azaindolylmaleimide — 0.0340
Compound 46 Azaindolylmaleimide — 0.0360
Compound 5a Bisindolylmaleimide — 0.0180
Compound 8b Triazole — 0.2800
CT20026 Aminopyridine 0.0040 0.0040
I5 Anilinoarylmaleimide 0.0760 0.1600
SB216763 Arylindolemaleimide 0.0340 0.0750
SB415286 Anilinomaleimide 0.0780 0.1300
GSK-3: glycogen synthase kinase.
such as HSTF-1; by reducing death-related signals, such
as cytochrome c, thereby reﬂecting mitochondrial injury,
activated caspase-3, and cleaved forms of poly (ADP-ribose)
polymerase; by decreasing inﬂammation-related signals such
as cyclooxygenase-2 and intercellular adhesion molecule 2.
Why and how GSK-3β isactivated, however,remain tobe
elucidated.Basedonpreviousreports,includingstudiesfrom
ourlaboratory,wehypothesizethatthedisturbanceofsignal-
ing proteins upstream of GSK-3β, which control the activity
or the expression of GSK-3β, might cause overactivation or
overexpression of GSK-3β. For example, a decrease in or the
abnormality of proteins involved in the PI3K pathway, such
as PI3K and Akt, might be associated with overactivation of
GSK-3β in ALS, considering the many reports showing that
a speciﬁc PI3K activator or materials with a PI3K-activating
eﬀect modify GSK-3β activity and reduce motoneuronal cell
death [41–46]. There was, however, a report showing that
changes in the PI3K/Akt survival pathway were not found
in spinal cord motor neurons in a mouse model of familial
ALS [47]. Clear answers to these issues should be elucidated
in future studies and couldbe helpful for the developmentof
new and eﬀective therapeutic strategies for ALS.
5.The DevelopmentofNew GSK-3β Inhibitors
Considering that GSK-3β is overactivated in ALS and that
it plays an important role in motoneuronal cell death, the
development of new GSK-3β inhibitors might be helpful
in the treatment of ALS, so there are many new GSK-3β
inhibitors under development (Table 1)[ 48]. In the devel-
opment of new GSK-3β inhibitors, it should be considered
that overinhibition of GSK-3β activity can conversely cause
neuronal cell death because of GSK-3β’s role in a variety of
cellular processes such as glucose metabolism. We previously
showed that treatment with higher concentrations of GSK-
3β inhibitors, above the optimal concentrations that prevent
neuronal cell death by oxidative stress, induced neuronal cell
death [49].
Another consideration is that chronic inhibition of
GSK-3β could increase several transcription factors and
β-catenin, which could contribute to the development of
cancer. In detail, β-catenin binds to transcription factors
and to other proteins, such as axin, a component of the
Wnt signaling pathway. Active GSK-3β phosphorylates β-
catenin and is involved in the degradation of the β-catenin
complex. Chronic inhibition of GSK-3β, however, increases
β-catenin andotherproteins,suchasadenomatouspolyposis
coli (APC), and this process may lead to higher incidences of
cancer [24, 25].
Taken together, newly developed GSK-3β inhibitors for
the treatment of ALS should have an optimal and balanced
inhibitory eﬀect on GSK-3β, and the appropriate dose
needs to be carefully examined. Furthermore, it is extremely
desirable to identify the GSK-3β inhibitor dose that results
in no eﬀect on β-catenin degradation, to prevent cancer
formation.
6.Conclusions
GSK-3β plays extremely important roles in the motoneu-
ronal cell death related to ALS, and the development of
speciﬁc GSK-3 inhibitors might be an eﬀective strategy for
the treatment of ALS.
Acknowledgment
This paper was supported by a Grant from the Korea
Healthcare Technology R&D Project, Ministry for Health,
Welfare, and Family Aﬀairs, RepublicofKorea (A101712and
A091049).4 Neurology Research International
References
[1] A. Al-Chalabi and P. N. Leigh, “Recent advances in amy-
otrophic lateral sclerosis,” Current Opinion in Neurology,v o l .
13, no. 4, pp. 397–405, 2000.
[2] J. S. Henkel, J. I. Engelhardt, L. Sikl´ os et al., “Presence of
dendritic cells, MCP-1, and activated microglia/macrophages
in amyotrophic lateral sclerosis spinal cord tissue,” Annals of
Neurology, vol. 55, no. 2, pp. 221–235, 2004.
[ 3 ]S .H .K i m ,J .S .H e n k e l ,D .R .B e e r se ta l . ,“ P A R Pe x p r e s s i o n
is increased in astrocytes but decreased in motor neurons
in the spinal cord of sporadic ALS patients,” Journal of
Neuropathology and Experimental Neurology,v ol.62,no .1,p p .
88–103, 2003.
[4] J. M. McCord and M. E. Gurney, “Mutant mice, CuZn super-
oxide dismutase, and motor neuron degeneration,” Science,
vol. 266, no. 5190, pp. 1586–1587, 1994.
[5] W. Robberecht, “Oxidative stress in amyotrophic lateral
sclerosis,”Journal of Neurology, vol. 247, no. 1, pp. 1–6, 2000.
[6] D. R. Rosen, T. Siddique, D. Patterson et al., “Mutations in
Cu/Zn superoxide dismutase gene are associated with familial
amyotrophic lateral sclerosis,” Nature, vol. 362, no. 6415, pp.
59–62, 1993.
[ 7 ]M .S o n ,C .D .C l o y d ,J .D .R o t h s t e i n ,B .R a j e n d r a n ,a n dJ .L .
Elliott, “Aggregate formation in Cu,Zn superoxide dismutase-
related proteins,” Journal of Biological Chemistry, vol. 278, no.
16, pp. 14331–14336, 2003.
[8] R. W.Strange, S.Antonyuk, M.A. Houghet al.,“Thestructure
of holoandmetal-deﬁcient wild-type humanCu, Zn superox-
ide dismutaseand its relevance to familial amyotrophic lateral
sclerosis,”JournalofMolecularBiology,vol.328,no.4,pp.877–
891, 2003.
[ 9 ]N .E m b i ,D .B .R y l a t t ,a n dP .C o h e n ,“ G l y c o g e ns y n t h a s e
kinase-3 from rabbit skeletal muscle. Separation from cyclic-
AMP-dependent protein kinase and phosphorylase kinase,”
European Journal of Biochemistry, vol. 107, no. 2, pp. 519–527,
1980.
[10] R. S. Jope and G. V. W. Johnson, “The glamour and gloom
of glycogen synthase kinase-3,” Trends in Biochemical Sciences,
vol. 29, no. 2, pp. 95–102, 2004.
[11] J. R. Woodgett, “cDNA cloning and properties of glycogen
synthase kinase-3,” Methods in Enzymology, vol. 200, pp. 564–
577, 1991.
[ 1 2 ]G .C h e n ,K .A .B o w e r ,C .M a ,S .F a n g ,C .J .T h i e l e ,a n d
J. Luo, “Glycogen synthase kinase 3β (GSK3β)m e d i a t e s6 -
hydroxydopamine-induced neuronal death,” FASEB Journal,
vol. 18, no. 10, pp. 1162–1164, 2004.
[ 1 3 ] J .H .H u ,H .Z h a n g ,R .W a g e y ,C .K r i e g e r ,a n dS .L .
Pelech, “Protein kinase and protein phosphatase expression
in amyotrophic lateral sclerosis spinal cord,” Journal of Neu-
rochemistry, vol. 85, no. 2, pp. 432–442, 2003.
[14] E.H.KooandR.Kopan,“Potentialroleofpresenilin-regulated
signaling pathways in sporadic neurodegeneration,” Nature
Medicine, vol. 10, pp. S26–S33, 2004.
[15] S. H. Koh, Y. B. Lee, K. S. Kim et al., “Role of GSK-3β activity
in motorneuronal cell death induced by G93A orA4V mutant
hSOD1 gene,” European Journal of Neuroscience,v o l .2 2 ,n o .2 ,
pp. 301–309, 2005.
[16] P. Watcharasit, G. N. Bijur, L. Song, J. Zhu, X. Chen, and R.
S. Jope, “Glycogen synthase kinase-3beta (GSK3beta) binds
to and promotes the actions of p53,” Journal of Biological
Chemistry, vol. 278, no. 49, pp. 48872–48879, 2003.
[17] G. N. Bijur and R. S. Jope, “Opposing actions of phos-
phatidylinositol 3-kinase and glycogen synthase kinase-3β in
the regulation of HSF-1 activity,” Journal of Neurochemistry,
vol. 75, no. 6, pp. 2401–2408, 2000.
[18] G. N. Bijur and R. S. Jope, “Proapoptotic stimuli induce
nuclear accumulationofglycogensynthasekinase-3β,” Journal
of Biological Chemistry, vol. 276, no. 40, pp. 37436–37442,
2001.
[19] C. A. Grimes and R. S. Jope, “The multifaceted roles of
glycogen synthase kinase 3β in cellular signaling,” Progress in
Neurobiology, vol. 65, no. 4, pp. 391–426, 2001.
[20] T. Takadera and T. Ohyashiki, “Glycogen synthase kinase-3
inhibitors prevent caspase-dependent apoptosis induced by
ethanol in cultured rat cortical neurons,” European Journal of
Pharmacology, vol. 499, no. 3, pp. 239–245, 2004.
[21] M. Pap and G. M. Cooper, “Role of glycogen synthase
kinase-3inthephosphatidylinositol3-kinase/Aktcellsurvival
pathway,” Journal of Biological Chemistry, vol. 273, no. 32, pp.
19929–19932, 1998.
[22] M.PapandG.M.Cooper,“Roleoftranslationinitiationfactor
2B in control of cell survival by the phosphatidylinositol 3-
kinase/Akt/glycogen synthase kinase 3β signaling pathway,”
Molecular and Cellular Biology, vol. 22, no. 2, pp. 578–586,
2002.
[23] L. C. Cantley, “The phosphoinositide 3-kinase pathway,”
Science, vol. 296, no. 5573, pp. 1655–1657, 2002.
[24] T. C. Dale, “Signaltransduction by the Wnt familyof ligands,”
Biochemical Journal, vol. 329, no. 2, pp. 209–223, 1998.
[25] J. Huelsken and J. Behrens, “The Wnt signalling pathway,”
Journal of Cell Science, vol. 115, no. 21, pp. 3977–3978, 2002.
[26] B. A. Hemmings, D. Yellowlees, J. C. Kernohan, and P. Cohen,
“Puriﬁcationofglycogensynthasekinase3fromrabbitskeletal
muscle. Copuriﬁcation with the activating factor (FA) of the
(Mg-ATP) dependent protein phosphatase,” European Journal
of Biochemistry, vol. 119, no. 3, pp. 443–451, 1981.
[ 2 7 ]F .K i r s c h e n b a u m ,S .C .H s u ,B .C o r d e l l ,a n dJ .V .M c C a r t h y ,
“Glycogen synthase kinase-3β regulates presenilin 1 C-
terminal fragment levels,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .
276, no. 33, pp. 30701–30707, 2001.
[ 2 8 ]C .J .P h i e l ,C .A .W i l s o n ,V .M .Y .L e e ,a n dP .S .K l e i n ,
“GSK-3αregulates productionofAlzheimer’sdiseaseamyloid-
β peptides,” Nature, vol. 423, no. 6938, pp. 435–439, 2003.
[ 2 9 ]H .D e c k e r ,K .Y .L o ,S .M .U n g e r ,S .T .F e r r e i r a ,a n dM .
A. Silverman, “Amyloid-β peptide oligomers disrupt axonal
transport through an NMDA receptor-dependent mechanism
that is mediated by glycogen synthase kinase 3β in primary
cultured hippocampal neurons,” Journal of Neuroscience,v o l .
30, no. 27, pp. 9166–9171, 2010.
[30] T. Duka, M. Rusnak, R. E. Drolet et al., “Alpha-synuclein
induces hyperphosphorylation of Tau in the MPTP model of
Parkinsonism,”FASEB Journal, vol. 20, no. 13, pp. 2302–2312,
2006.
[ 3 1 ]H .E n d o ,C .N i t o ,H .K a m a d a ,T .N i s h i ,a n dP .H .C h a n ,
“Activation of the Akt/GSK3β signaling pathway mediates
survival of vulnerable hippocampal neurons after transient
globalcerebralischemiainrats,”Journal ofCerebral BloodFlow
and Metabolism, vol. 26, no. 12, pp. 1479–1489, 2006.
[32] S. H. Koh, A. R. Yoo, D. I. Chang, S. J. Hwang, and
S. H. Kim, “Inhibition of GSK-3 reduces infarct volume
and improves neurobehavioral functions,” Biochemical and
Biophysical Research Communications, vol.371,no.4, pp. 894–
899, 2008.
[ 3 3 ]S .G u o ,K .A r a i ,M .F .S t i n s ,D .M .C h u a n g ,a n dE .H .L o ,
“Lithium upregulates vascular endothelial growth factor in
brain endothelial cells and astrocytes,” Stroke, vol. 40, no. 2,
pp. 652–655, 2009.Neurology Research International 5
[ 3 4 ]A .B .G o l d ,N .H e r r m a n n ,a n dK .L .L a n c tˆ ot, “Lithium and its
neuroprotective and neurotrophic eﬀects: potential treatment
for post-ischemic stroke sequelae,” Current Drug Targets,v o l .
12, no. 2, pp. 243–255, 2011.
[35] W. Yang, C. Leystra-Lantz, and M. J. Strong, “Upregulation of
GSK3β expression in frontal and temporal cortex in ALS with
cognitive impairment (ALSci),” Brain Research, vol. 1196, pp.
131–139, 2008.
[36] F. Sugai, Y. Yamamoto,K. Miyaguchi et al.,“Beneﬁt of valproic
acid in suppressing disease progression of ALS model mice,”
European Journal of Neuroscience, vol. 20, no. 11, pp. 3179–
3183, 2004.
[ 3 7 ]H .L .F e n g ,Y .L e n g ,C .H .M a ,J .Z h a n g ,M .R e n ,a n dD .M .
Chuang, “Combined lithium and valproate treatment delays
disease onset, reduces neurological deﬁcits and prolongs
survival in an amyotrophic lateral sclerosis mouse model,”
Neuroscience, vol. 155, no. 3, pp. 567–572, 2008.
[38] S. H. Koh, Y. Kim, H. Y. Kim, S. Hwang, C. H. Lee, and S.




[39] S. H. Koh, H. Kwon, K. S. Kim et al., “Epigallocatechin gallate
prevents oxidative-stress-induced death of mutant Cu/Zn-
superoxide dismutase (G93A) motoneuron cells by alteration
of cell survival and death signals,” Toxicology, vol. 202, no. 3,
pp. 213–225, 2004.
[40] J. Calder´ o, N. Brunet, O. Tarabal et al., “Lithium prevents
excitotoxic cell death of motoneurons in organotypic slice
cultures ofspinalcord,”Neuroscience,vol.165,no.4,pp.1353–
1369, 2010.
[41] S. H. Koh, S. H. Kim, H. Kwon et al., “Phosphatidylinositol-
3k i n a s e / A k ta n dG S K - 3m e d i a t e dc y t o p r o t e c t i v ee ﬀect of
epigallocatechin gallate on oxidative stress-injured neuronal-
diﬀerentiated N18D3cells,”NeuroToxicology,v ol.25,no .5,pp .
793–802, 2004.
[42] H. Warita, Y. Manabe, T. Murakami, Y. Shiro, I. Nagano, and
K. Abe, “Early decrease of survival signal-related proteins in
spinalmotorneuronsofpresymptomatictransgenicmicewith
a mutant SOD1 gene,” Apoptosis, vol. 6, no. 5, pp. 345–352,
2001.
[43] I. Nagano, T. Murakami, Y. Manabe, and K. Abe, “Early
decrease of survival factors and DNA repair enzyme in
spinalmotorneurons of presymptomatic transgenic mice that
express a mutant SOD1 gene,” Life Sciences,v o l .7 2 ,n o .4 - 5 ,
pp. 541–548, 2002.
[ 4 4 ]B .L i ,W .X u ,C .L u o ,D .G o z a l ,a n dR .L i u ,“ V E G F - i n d u c e d
activation of the PI3-K/Akt pathway reduces mutant SOD1-
mediated motor neuron cell death,” Molecular Brain Research,
vol. 111, no. 1-2, pp. 155–164, 2003.
[ 4 5 ]L .T o l o s a ,M .M i r ,V .J .A s e n s i o ,G .O l m o s ,a n dJ .L l a d ´ o,
“Vascular endothelial growth factor protects spinal cord
motoneurons against glutamate-induced excitotoxicity via
phosphatidylinositol3-kinase,”Journal of Neurochemistry,v o l .
105, no. 4, pp. 1080–1090, 2008.
[ 4 6 ] L .T o l o s a ,M .M i r ,G .O l m o s ,a n dJ .L l a d ´ o, “Vascular
endothelial growth factor protects motoneurons from serum
deprivation-induced cell death through phosphatidylinositol
3-kinase-mediated p38 mitogen-activated protein kinaseinhi-
bition,” Neuroscience, vol. 158, no. 4, pp. 1348–1355, 2009.
[47] M. Peviani, C. Cheroni, F. Troglio, M. Quarto, G. Pelicci,
and C. Bendotti, “Lack of changes in the PI3K/AKT survival
pathwayinthespinalcordmotorneuronsofamousemodel of
familial amyotrophic lateral sclerosis,” Molecular and Cellular
Neuroscience, vol. 34, no. 4, pp. 592–602, 2007.
[48] L. Meijer, M. Flajolet, and P. Greengard, “Pharmacological
inhibitors of glycogen synthase kinase 3,” Trends in Pharma-
cological Sciences,vol. 25, no. 9, pp. 471–480, 2004.
[49] K. Y. Lee, S. H. Koh, M. Y. Noh, K. W. Park, Y. J. Lee, and
S. H. Kim, “Glycogen synthase kinase-3β activity plays very
important roles in determining the fate of oxidative stress-
inﬂicted neuronal cells,” Brain Research, vol. 1129, no. 1, pp.
89–99, 2007.